Martin Sadowski

Dr. Martin Sadowski

Department of Neurology, NYU School of Medicine, NY, USA
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2003 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
YWYoussef Zaim Wadghiri
Youssef Zaim Wadghiri
ESEinar M. Sigurdsson
Einar M. Sigurdsson
MSMartin Sadowski
Martin Sadowski
JEJames I. Elliott
James I. Elliott
YLYongsheng Li
Yongsheng Li
DTDaniel H. Turnbull
Daniel H. Turnbull
The presence of amyloid‐β (Aβ) plaques in the brain is a hallmark pathological feature of Alzheimer's disease (AD). Transgenic mice overexpressing mutant amyloid precursor protein (APP), or both mutant APP and presenilin‐1 (APP/PS1), develop Aβ plaques similar to those in AD patients, and have been proposed as animal models in which to test experimental therapeutic approaches for the clearance of Aβ. However, at present there is no in vivo whole‐brain imaging method to detect Aβ plaques in mice or men. A novel method is presented to detect Aβ plaques in the brains of transgenic mice by magnetic resonance microimaging (μMRI). This method uses Aβ1‐40 peptide, known for its high binding affinity to Aβ, magnetically labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). Intraarterial injection of magnetically labeled Aβ1‐40, with mannitol to transiently open the blood–brain barrier (BBB), enabled the detection of many Aβ plaques. Furthermore, the numerical density of Aβ plaques detected by μMRI and by immunohistochemistry showed excellent correlation. This approach provides an in vivo method to detect Aβ in AD transgenic mice, and suggests that diagnostic MRI methods to detect Aβ in AD patients may ultimately be feasible. Magn Reson Med 50:293–302, 2003.

1 March 2006 in Neurobiology of Aging
Verified
Journal Article
Closed access
MLM.J. de Leon
M.J. de Leon
SDS. DeSanti
S. DeSanti
RZR. Zinkowski
R. Zinkowski
PMP.D. Mehta
P.D. Mehta
DPD. Pratico
D. Pratico
PDP. Davies
P. Davies

6 March 2023 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MSMarisol Soula
Marisol Soula
AMAlejandro Martín-Ávila
Alejandro Martín-Ávila
YZYiyao Zhang
Yiyao Zhang
ADAnnika Dhingra
Annika Dhingra
NNNoam Nitzan
Noam Nitzan
GBGyörgy Buzsáki
György Buzsáki

5 December 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MSMartin Sadowski
Martin Sadowski
JPJoanna Pankiewicz
Joanna Pankiewicz
HSHenrieta Scholtzova
Henrieta Scholtzova
PMPankaj D. Mehta
Pankaj D. Mehta
FPFrances Prelli
Frances Prelli
Thomas WisniewskiThomas Wisniewski
Thomas Wisniewski
The amyloid-β (Aβ) cascade hypothesis of Alzheimer's disease (AD) maintains that accumulation of Aβ peptide constitutes a critical event in the early disease pathogenesis. The direct binding between Aβ and apolipoprotein E (apoE) is an important factor implicated in both Aβ clearance and its deposition in the brain's parenchyma and the walls of meningoencephalic vessels as cerebral amyloid angiopathy. With the aim of testing the effect of blocking the apoE/Aβ interaction in vivo as a potential novel therapeutic target for AD pharmacotherapy, we have developed Aβ12-28P, which is a blood-brain-barrier-permeable nontoxic, and nonfibrillogenic synthetic peptide homologous to the apoE binding site on the full-length Aβ. Aβ12-28P binds with high affinity to apoE, preventing its binding to Aβ, but has no direct effect on Aβ aggregation. Aβ12-28P shows a strong pharmacological effect in vivo . Its systemic administration resulted in a significant reduction of Aβ plaques and cerebral amyloid angiopathy burden and a reduction of the total brain level of Aβ in two AD transgenic mice models. The treatment did not affect the levels of soluble Aβ fraction or Aβ oligomers, indicating that inhibition of the apoE/Aβ interaction in vivo has a net effect of increasing Aβ clearance over deposition and at the same time does not create conditions favoring formation of toxic oligomers. Furthermore, behavioral studies demonstrated that treatment with Aβ12-28P prevents a memory deficit in transgenic animals. These findings provide evidence of another therapeutic approach for AD.

31 May 2006 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
JPJoanna Pankiewicz
Joanna Pankiewicz
FPFrances Prelli
Frances Prelli
MSMan‐Sun Sy
Man‐Sun Sy
RKRichard J. Kascsak
Richard J. Kascsak
RKRegina B. Kascsak
Regina B. Kascsak
Thomas WisniewskiThomas Wisniewski
Thomas Wisniewski

1 May 2004 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
MSMartin Sadowski
Martin Sadowski
JPJoanna Pankiewicz
Joanna Pankiewicz
HSHenrieta Scholtzova
Henrieta Scholtzova
YJYong Ji
Yong Ji
DQDavid Quartermain
David Quartermain
Thomas WisniewskiThomas Wisniewski
Thomas Wisniewski
In Alzheimer disease (AD) patients, early memory dysfunction is associated with glucose hypometabolism and neuronal loss in the hippocampus. Double transgenic (Tg) mice co-expressing the M146L presenilin 1 (PS1) and K670N/ M671L, the double “Swedish” amyloid precursor protein (APP) mutations, are a model of AD amyloid-β deposition (Aβ) that exhibits earlier and more profound impairments of working memory and learning than single APP mutant mice. In this study we compared performance on spatial memory tests, regional glucose metabolism, Aβ deposition, and neuronal loss in APP/PS1, PS1, and non-Tg (nTg) mice. At the age of 2 months no significant morphological and metabolic differences were detected between 3 studied genotypes. By 8 months, however, APP/PS1 mice developed selective impairment of spatial memory, which was significantly worse at 22 months and was accompanied by reduced glucose utilization in the hippocampus and a 35.8% dropout of neurons in the CA1 region. PS1 mice exhibited a similar degree of neuronal loss in CA1 but minimal memory deficit and no impairment of glucose utilization compared to nTg mice. Deficits in 22 month APP/PS1 mice were accompanied by a substantially elevated Aβ load, which rose from 2.5% ± 0.4% at 8 months to 17.4% ± 4.6%. These findings implicate Aβ or APP in the behavioral and metabolic impairments in APP/PS1 mice and the failure to compensate functionally for PS1-related hippocampal cell loss.